Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,947 | 123 | 99.4% |
| Education | $28.35 | 3 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $907.20 | 14 | $0 (2022) |
| Novo Nordisk Inc | $895.64 | 18 | $0 (2023) |
| Esperion Therapeutics, Inc. | $511.49 | 11 | $0 (2024) |
| Amgen Inc. | $435.06 | 5 | $0 (2023) |
| PFIZER INC. | $414.43 | 17 | $0 (2020) |
| AbbVie Inc. | $327.45 | 16 | $0 (2021) |
| Lilly USA, LLC | $199.30 | 4 | $0 (2022) |
| Bayer HealthCare Pharmaceuticals Inc. | $172.54 | 2 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $157.42 | 14 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $145.96 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $116.57 | 2 | Esperion Therapeutics, Inc. ($116.57) |
| 2023 | $175.68 | 2 | Amgen Inc. ($95.67) |
| 2022 | $711.07 | 11 | Novo Nordisk Inc ($200.25) |
| 2021 | $870.42 | 16 | AstraZeneca Pharmaceuticals LP ($250.00) |
| 2020 | $317.83 | 7 | Esperion Therapeutics, Inc. ($96.84) |
| 2019 | $623.25 | 31 | AbbVie, Inc. ($163.71) |
| 2018 | $1,119 | 23 | Novo Nordisk Inc ($256.31) |
| 2017 | $1,042 | 34 | Novo Nordisk Inc ($143.78) |
All Payment Transactions
126 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/22/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $24.73 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 06/12/2024 | Esperion Therapeutics, Inc. | NEXLIZET (Drug), NEXLETOL | Food and Beverage | In-kind items and services | $91.84 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 09/28/2023 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $95.67 | General |
| Category: Cardiology | ||||||
| 05/04/2023 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $80.01 | General |
| Category: Obesity | ||||||
| 10/13/2022 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $64.54 | General |
| Category: Diabetes | ||||||
| 06/23/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $84.94 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/22/2022 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Obesity | ||||||
| 06/10/2022 | Lilly USA, LLC | — | Education | In-kind items and services | $11.71 | General |
| 06/02/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $6.04 | General |
| Category: Diabetes | ||||||
| 05/13/2022 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $6.57 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 04/04/2022 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $96.45 | General |
| Category: Genetic Disease | ||||||
| 03/31/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $107.95 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/24/2022 | Esperion Therapeutics, Inc. | NEXLIZET (Drug), NEXLETOL | Food and Beverage | In-kind items and services | $124.46 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 03/11/2022 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $4.67 | General |
| Category: Obesity | ||||||
| 01/28/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $78.74 | General |
| Category: Cardio-renal | ||||||
| 12/20/2021 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $4.74 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 12/03/2021 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $93.80 | General |
| Category: Cardio-renal | ||||||
| 12/03/2021 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $8.64 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 11/16/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 11/01/2021 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $8.05 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/21/2021 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $85.34 | General |
| Category: Diabetes | ||||||
| 09/20/2021 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $7.48 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 09/17/2021 | Medtronic, Inc. | Minimed 770G System (Device) | Food and Beverage | In-kind items and services | $20.38 | General |
| Category: Durable Pump | ||||||
| 09/01/2021 | Esperion Therapeutics, Inc. | NEXLIZET (Drug), NEXLETOL | Food and Beverage | In-kind items and services | $57.50 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 08/26/2021 | AbbVie Inc. | SYNTHROID (Drug) | Food and Beverage | In-kind items and services | $11.37 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 726 | 1,185 | $252,615 | $81,314 |
| 2022 | 13 | 682 | 1,118 | $244,565 | $84,385 |
| 2021 | 17 | 853 | 1,673 | $305,319 | $117,383 |
| 2020 | 16 | 838 | 1,917 | $337,675 | $116,245 |
All Medicare Procedures & Services
59 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 295 | 519 | $127,060 | $34,077 | 26.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 51 | 193 | $33,245 | $12,263 | 36.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 79 | 85 | $34,955 | $11,841 | 33.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 41 | 41 | $5,535 | $5,406 | 97.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 46 | 53 | $15,635 | $5,197 | 33.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 38 | 38 | $14,920 | $5,104 | 34.2% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 12 | 12 | $4,305 | $1,947 | 45.2% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 30 | 30 | $5,590 | $1,788 | 32.0% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 34 | 52 | $4,995 | $1,444 | 28.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 12 | 74 | $1,970 | $764.94 | 38.8% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 33 | 33 | $1,790 | $619.12 | 34.6% |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | Office | 2023 | 32 | 32 | $1,735 | $590.20 | 34.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 23 | 23 | $880.00 | $271.86 | 30.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 310 | 569 | $127,415 | $39,403 | 30.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 68 | 73 | $32,290 | $11,626 | 36.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 47 | 185 | $30,775 | $10,705 | 34.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 45 | 50 | $13,430 | $5,155 | 38.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 35 | 35 | $7,275 | $4,746 | 65.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 35 | 35 | $13,105 | $4,543 | 34.7% |
| 99495 | Transitional care management services for problem of moderate complexity | Office | 2022 | 17 | 18 | $5,690 | $3,047 | 53.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 15 | 18 | $5,125 | $1,979 | 38.6% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 27 | 50 | $4,995 | $1,377 | 27.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 14 | 16 | $1,580 | $658.20 | 41.7% |
| G0444 | Annual depression screening, 15 minutes | Office | 2022 | 24 | 24 | $1,085 | $454.29 | 41.9% |
| G0442 | Annual alcohol misuse screening, 15 minutes | Office | 2022 | 23 | 23 | $1,030 | $452.30 | 43.9% |
About Dr. Christopher Coakley, M.D
Dr. Christopher Coakley, M.D is a Internal Medicine healthcare provider based in Plymouth, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1780750455.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Coakley, M.D has received a total of $4,976 in payments from pharmaceutical and medical device companies, with $116.57 received in 2024. These payments were reported across 126 transactions from 22 companies. The most common payment nature is "Food and Beverage" ($4,947).
As a Medicare-enrolled provider, Coakley has provided services to 3,099 Medicare beneficiaries, totaling 5,893 services with total Medicare billing of $399,328. Data is available for 4 years (2020–2023), covering 59 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Diabetes & Metabolism
- Location Plymouth, MA
- Active Since 11/27/2006
- Last Updated 03/11/2008
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1780750455
Products in Payments
- FARXIGA (Drug) $777.21
- NEXLIZET (Drug) $451.28
- Repatha (Biological) $435.06
- Synthroid (Drug) $316.08
- Victoza (Drug) $226.36
- Tresiba (Drug) $201.67
- Kerendia (Drug) $172.54
- EUCRISA (Drug) $167.82
- ENTRESTO (Drug) $157.42
- Ozempic (Drug) $149.88
- XARELTO (Drug) $145.96
- CHANTIX (Drug) $134.24
- t-slim insulin pump (Device) $130.43
- SYMBICORT (Drug) $129.99
- Saxenda (Drug) $129.96
- PRALUENT ALIROCUMAB INJECTION (Biological) $120.72
- Korlym (Drug) $107.95
- ELIQUIS (Drug) $103.88
- RYBELSUS (Drug) $97.05
- TALTZ (Drug) $96.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Plymouth
Ms. Beverly Lewis, Md, MD
Internal Medicine — Payments: $171,186
Piotr Lazowski, Md, MD
Internal Medicine — Payments: $112,141
Dr. Jeff The, D.o, D.O
Internal Medicine — Payments: $7,992
Dr. Eugene Valsky, M.d, M.D
Internal Medicine — Payments: $6,811
Lauren Strazzula, M.d, M.D
Internal Medicine — Payments: $5,805
Dr. Anand Singla, Mbbs, MBBS
Internal Medicine — Payments: $5,497